Disease Characteristics, Quality of Life, and Work Productivity by Enthesitis Site: Real- World Data From the US Corrona Psoriatic Arthritis/Spondyloarthritis Registry

From the Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA; Corrona, LLC, Waltham, MA, USA; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. This study was sponsored by Corrona, LLC. Corrona, LLC, has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between Corrona, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript. Support for third-party writing assistance for this manuscript, furnished by Kheng Bekdache, PhD, of Health Interactions, Inc., was provided by Novartis Pharmaceuticals Corporation, East Hanover, NJ. Address correspondence to: Philip Mease MD, MACR, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122; email: pmease@philipmease.com

From the Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA; Corrona, LLC, Waltham, MA, USA; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. This study was sponsored by Corrona, LLC. Corrona, LLC, has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between Corrona, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript. Support for third-party writing assistance for this manuscript, furnished by Kheng Bekdache, PhD, of Health Interactions, Inc., was provided by Novartis Pharmaceuticals Corporation, East Hanover, NJ. Address correspondence to: Philip Mease MD, MACR, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122; email: pmease@philipmease.com

From the Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA; Corrona, LLC, Waltham, MA, USA; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. This study was sponsored by Corrona, LLC. Corrona, LLC, has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between Corrona, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript. Support for third-party writing assistance for this manuscript, furnished by Kheng Bekdache, PhD, of Health Interactions, Inc., was provided by Novartis Pharmaceuticals Corporation, East Hanover, NJ. Address correspondence to: Philip Mease MD, MACR, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122; email: pmease@philipmease.com

From the Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA; Corrona, LLC, Waltham, MA, USA; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. This study was sponsored by Corrona, LLC. Corrona, LLC, has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between Corrona, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript. Support for third-party writing assistance for this manuscript, furnished by Kheng Bekdache, PhD, of Health Interactions, Inc., was provided by Novartis Pharmaceuticals Corporation, East Hanover, NJ. Address correspondence to: Philip Mease MD, MACR, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122; email: pmease@philipmease.com

From the Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA; Corrona, LLC, Waltham, MA, USA; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. This study was sponsored by Corrona, LLC. Corrona, LLC, has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between Corrona, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript. Support for third-party writing assistance for this manuscript, furnished by Kheng Bekdache, PhD, of Health Interactions, Inc., was provided by Novartis Pharmaceuticals Corporation, East Hanover, NJ. Address correspondence to: Philip Mease MD, MACR, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122; email: pmease@philipmease.com

From the Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA; Corrona, LLC, Waltham, MA, USA; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. This study was sponsored by Corrona, LLC. Corrona, LLC, has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between Corrona, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript. Support for third-party writing assistance for this manuscript, furnished by Kheng Bekdache, PhD, of Health Interactions, Inc., was provided by Novartis Pharmaceuticals Corporation, East Hanover, NJ. Address correspondence to: Philip Mease MD, MACR, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122; email: pmease@philipmease.com

From the Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA; Corrona, LLC, Waltham, MA, USA; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. This study was sponsored by Corrona, LLC. Corrona, LLC, has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between Corrona, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript. Support for third-party writing assistance for this manuscript, furnished by Kheng Bekdache, PhD, of Health Interactions, Inc., was provided by Novartis Pharmaceuticals Corporation, East Hanover, NJ. Address correspondence to: Philip Mease MD, MACR, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122; email: pmease@philipmease.com